ENTPD1 and ovarian carcinoma: Small molecules that reprogram immunometabolism (e.g., amitriptyline affecting tryptophan metabolism) decrease CD39+PD-1+ T cells and synergize with PD-1 inhibitors in ovarian cancer (87).